Breaking News

Cenduit Adds Key Management

Roth and Ferrandiz will work to maintain IRT customer service and support

Cenduit, LLC has appointed Andrew Roth as global head of technology and Kirsten Ferrandiz as senior director of account management. Both will report directly to the vice president of customer and project management and will work to maintain high levels of customer service and support.

Mr. Roth has extensive experience with software systems development and design, from communications and telecommunications, to information technology. He has held leadership positions in R&D across a variety of industries. Most recently he served as director of engineering services at Tekelec, where he was responsible for engineering infrastructure for a global R&D organization.

Ms. Ferrandiz has nearly 20 years of experience in the life sciences industry, including extensive management background in process improvement, software systems development and design within the Interactive Response Technologies (IRT) arena. She has held leadership positions in both service operations and product development. Most recently she served as senior director of product management/strategy at Oracle, where she collaborated on IRT product roadmaps and managed key product releases.

Dr. Jogin Desai, Cenduit’s chief executive officer, said, “Andy brings deep experience in technology both in implementation and process. His expertise will be integral to the organization as Cenduit rolls out innovative new products and continues to expand its business. Kirsten joins us with significant experience in the Interactive Response Technology (IRT) space as well as a broad product development background. She is a talented addition to our management team and will be working not only to improve Cenduit’s service offering but also to further develop key customer relationships.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters